Login
Zimmer Biomet Holdings NYSE: ZBH
| Name | Zimmer Biomet Holdings |
| Ticker | ZBH |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Price | 146.93 |
| 52W Low/High | 80.63 / 160.40 |
| Market cap | 30 B |
| 1Y Total Return |
7.47%
Above Average |
| 1Y Volatility |
47.45%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Details
| Ticker | ZBH |
| Name | Zimmer Biomet Holdings |
| ISIN | US98956P1021 |
| CUSIP | 98956P102 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | US S&P 500 Index |
Share as of 10/16/20
| Close Price | 146.93 |
| 52W Low/High | 80.63 / 160.40 |
| Market cap | 30 B |
| 1Y Total Return |
7.47%
Above Average |
| 1Y Volatility |
47.45%
Less Risk |
| Beta | 1.11 |
| PE (trailing) |
918.31
High |
| 12M Dividends | 0.96 |
| Last Dividend Date | 9/29/20 |
| Dividend Yield | 0.65% |
Fin. Strength
| Net Profit Margin | 0.5% |
| Cash from Op. / Cur. Liabilities | 0.65 |
| Diluted Earnings / Share | 0.16 |
| ROE | 0.3% |
| ROIC | 0.0% |
| Price / Revenue | 4.3 |
| Price / Book | 2.6 |
| Price / CF | 21.7 |
| Current Ratio | 2.2 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.71 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
7,028
|
7,872
|
7,907
|
7,752
|
7,534
|
4,631
|
|
| Gross Profit |
4,999
|
5,625
|
5,655
|
5,611
|
5,032
|
3,451
|
|
| R&D |
422
|
411
|
381
|
375
|
344
|
193
|
|
| EBITDA |
977
|
993
|
1,813
|
2,013
|
1,811
|
951
|
|
| Operating Income |
-45
|
-12
|
772
|
1,002
|
777
|
570
|
|
| Net Income exc. Extra |
37
|
-
|
1,690
|
712
|
227
|
341
|
|
| per Share | |||||||
| Diluted avg Shares |
207
|
206
|
205
|
204
|
199
|
173
|
|
| EPS exc. Extra |
0.16
|
-1.77
|
8.27
|
3.49
|
1.15
|
1.97
|
|
| Dividend |
0.96
|
0.96
|
0.96
|
0.96
|
0.92
|
0.88
|
|
| Div. Yield (an.) |
0.80%
|
0.82%
|
0.86%
|
0.75%
|
0.76%
|
0.85%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
23,648
|
24,206
|
25,491
|
26,459
|
25,971
|
27,204
|
|
| Cash, Eq & Invt ShortTerm |
713
|
403
|
481
|
450
|
976
|
1,884
|
|
| Total Current Assets |
4,707
|
4,391
|
4,475
|
4,424
|
5,051
|
6,752
|
|
| Total Non-Current Assets |
18,941
|
19,815
|
21,016
|
22,035
|
20,921
|
20,453
|
|
| Intangibles |
15,920
|
17,118
|
18,593
|
19,410
|
18,364
|
17,672
|
|
| Total Liabilities |
12,004
|
12,544
|
13,447
|
16,180
|
16,422
|
17,078
|
|
| Total Current Liabilities |
2,161
|
3,678
|
1,854
|
2,996
|
2,101
|
2,163
|
|
| Long Term Debt |
9,843
|
8,866
|
11,593
|
13,183
|
14,321
|
14,915
|
|
| Shareholder equity |
11,641
|
11,659
|
12,043
|
10,279
|
9,548
|
10,124
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
1,399
|
1,448
|
1,750
|
1,696
|
1,214
|
888
|
|
| Depreciation |
1,014
|
1,016
|
1,056
|
1,072
|
1,023
|
372
|
|
| Cash from Investing |
-508
|
-649
|
-444
|
-1,783
|
-8
|
-7,921
|
|
| Capex |
500
|
698
|
426
|
546
|
451
|
312
|
|
| Cash from Financing |
-574
|
-872
|
-1,283
|
-447
|
-1,636
|
7,528
|
|
| Stock Issued |
165
|
106
|
96
|
164
|
-416
|
100
|
|
| Debt (LT) Issued |
-520
|
-778
|
-1,158
|
-392
|
-1,042
|
7,566
|
|
| Free Cash Flow |
-1,281
|
2,103
|
1,745
|
3,248
|
1,233
|
-34
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
0.5%
|
-
|
21.4%
|
9.2%
|
3.0%
|
7.4%
|
|
| NCFO / Op.Income |
-
|
-
|
226.7%
|
169.2%
|
156.3%
|
155.8%
|
|
| Current Ratio |
2.2
|
1.2
|
2.4
|
1.5
|
2.4
|
3.1
|
|
| Financial Leverage D/E |
0.71
|
0.75
|
0.79
|
1.04
|
1.16
|
1.19
|
|
| Return on Capital Avg |
0.0%
|
-0.1%
|
10.1%
|
5.2%
|
1.7%
|
3.3%
|
|
| Return on Shareholder Equity |
0.3%
|
-
|
15.1%
|
7.2%
|
2.3%
|
4.1%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available